Epstein Secrets

bserver), Sirna Therapeutics (NASDAQ: RNAI, acquired by Merck in 2006 for $1.1 billion), where he served as Chairman; Oriel Therapeutics (acquired by Novartis in 2010), where he served as Executive Chairman, and Pearl Therapeutics (acquired by AstraZeneca in 2012). Prior to joining Sprout, Jim was Chief Sci

oval process for generic biologics and granting exclusive marketing rights to original manufacturers for 12 years, (iv) increased drug rebates to the Medicaid program, and (v) disclosure requirements for financial relationships between various healthcare entities. Within the U.S., the pharmaceutical indust

Marley Natural, Irisa, Goodship, Grail, and Dutchy. TLRY has been active on the M&A front, with previously announced acquisitions / partnerships with Novartis, Authentic Brands and AB-Inbev, among others. Most recently, the company announced a C$419 mm acquisition of Manitoba Harvest, the global leader in h

e CBD market. Healthcare: Payor Perspective: Generally speaking, managed care does not cover OTC products, with the same being true for Medicare and Medicaid. Based on our conversations with a number of payors, whether CBD oils will be covered as a medical benefit by government sponsored health programs is

s, improving their effectiveness but shrinking their addressable markets. Drug companies will need to adapt their marketing strategies accordingly. Novartis CEO Joe Jimenez called out the explosion in DNA sequencing as a driver for R&D productivity "allowing new areas of discovery that have never been po

healthcare spending and its seemingly relentless growth are problematic for the US. Public spending on healthcare—primarily through the Medicare and Medicaid programs—is crowding out other state and national priorities, including education, social security, national defense, and deficit eduction. High he